文献速递甲状腺疾病

中高危乳头状甲状腺癌延迟手术与临床结局分析

Analysis of Delayed Surgery and Clinical Outcomes in Intermediate- and High-risk Papillary Thyroid Cancer.
PubMed 文献 · J Clin Endocrinol Metab · 2022-01-01

回顾性纳入中国西南3家三级医院871例中高危复发风险乳头状甲状腺癌患者,均行全甲状腺切除和放射性碘消融,按诊断至手术间隔分为<6个月、≥6至11个月、≥12个月三组,1年疗效满意率分别为64.7%、71.5%、66.1%(P=0.27),手术时机似乎不影响短期疾病结局。

要点

  • 中高危乳头状甲状腺癌诊断至手术中位间隔2个月(范围1-87个月)。
  • 三组1年疗效满意率分别为64.7%、71.5%、66.1%,差异无统计学显著(P=0.27)。
  • 按复发风险和T分期分层后,手术时机仍未见影响,需进一步研究长期预后。

核心结论

  • 手术时机似乎不影响中高危乳头状甲状腺癌患者的短期疾病结局,延迟手术对长期预后的影响需进一步研究。

研究设计与样本

  • 回顾性纳入中国西南3家三级医院连续收治的中高危复发风险乳头状甲状腺癌患者,均行全甲状腺切除和放射性碘消融。
  • 共纳入871例,按诊断至手术间隔分为<6个月(A组,624/871[71.6%])、≥6至11个月(B组,123/871[14.1%])、≥12个月(C组,124/871[14.2%])。

主要发现

  • 诊断至手术中位间隔2个月(范围1-87个月)。
  • 初始治疗后1年,A、B、C组分别有64.7%、71.5%、66.1%的患者达到疗效满意(P=0.27)。
  • 按中高危分类和所有T分期类别分析,均未观察到手术时机的影响。
  • 按放射性碘剂量分层(中等剂量组≤3.7 GBq[n=654],高活度组5.5 GBq[n=217])并进一步按手术时机细分后,结果未改变。

关键数值与推荐

  • 1年疗效满意定义为无乳头状甲状腺癌的临床、影像或生化证据。

局限性

  • 原文结论指出需进一步研究评估延迟手术对长期预后的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: The optimal timing to performing thyroid surgery following a diagnosis of papillary thyroid cancer (PTC) has yet to be fully defined. OBJECTIVE: We aimed to examine if a delayed surgery may worsen the clinical outcome of PTC patients with intermediate- to high-risk of recurrence. METHODS: All consecutive PTC patients with intermediate- to high-risk of recurrence who underwent total thyroidectomy and radioactive iodine (RAI) ablation at 3 tertiary hospitals in southwest China were retrospectively included. Excellent response at 1-year follow-up after initial therapy was defined as no clinical, imaging, or biochemical evidence of PTC. Association of the timing of surgery and excellent response rates. RESULTS: The study included 871 patients. The median time interval between PTC diagnosis and surgery was 2 months (range, 1-87 months). Patients were divided according to the timing of surgery, < 6 months (group A, 624/871 [71.6%]), ≥ 6 to 11 months (group B, 123/871 [14.1%]), or ≥ 12 months (group C, 124/871 [14.2%]). One year after initial therapy, 64.7%, 71.5%, and 66.1% of patients in groups A, B, and C, respectively, achieved excellent response (P = 0.27). The lack of impact of surgery timing was observed across intermediate- to high-risk classifications and all T stage categories. These findings did not change when we separately analyzed the groups according to RAI dose (intermediate-dose group: ≤ 3.7 GBq [n = 654], and high-activity group: 5.5 GBq [n = 217]) further subdivided according to the timing of surgery. CONCLUSION: Timing of surgery does not seem to affect short-term disease outcomes in intermediate- to high-risk PTC patients. Further research is necessary to assess the impact of delayed surgery on long-term prognosis.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Zhou H, Wu J, Shi L, et al. Analysis of Delayed Surgery and Clinical Outcomes in Intermediate- and High-risk Papillary Thyroid Cancer. J Clin Endocrinol Metab. 2022. PMID: 36056633. doi:10.1210/clinem/dgac502

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。